Mammalian somatic cell with modified RNA encoding reprogramming factors
Described herein are synthetic, modified RNAs for changing the phenotype of a cell, such as expressing a polypeptide or altering the developmental potential. Accordingly, provided herein are compositions, methods, and kits comprising synthetic, modified RNAs for changing the phenotype of a cell or cells. These methods, compositions, and kits comprising synthetic, modified RNAs can be used either to express a desired protein in a cell or tissue, or to change the differentiated phenotype of a cell to that of another, desired cell type.
1. An isolated, mammalian somatic cell comprising exogenously introduced synthetic, modified RNA encoding:
(i) Oct4,
(ii) Sox2,
(iii) Klf4, and
(iv) one or more of NANOG, c-MYC, and LIN28;
wherein each cytosine of the synthetic, modified RNA is replaced with 5-methylcytosine and each uracil of the synthetic, modified RNA is replaced with pseudouracil.
2. The cell of claim 1 , wherein the cell is a human cell.
3. The cell of claim 1 , wherein the synthetic, modified RNA further comprises a 5′ cap.
4. The cell of claim 3 , wherein the 5′ cap is a 5′ cap analog.
5. The cell of claim 4 , wherein the 5′ cap analog is a 5′ diguanosine cap.
6. The cell of claim 1 , wherein the synthetic, modified RNA does not comprise a 5′ triphosphate.
7. The cell of claim 1 , wherein the synthetic, modified RNA further comprises a poly(A) tail, a Kozak sequence, a 3′ untranslated region, a 5′ untranslated region, or any combination thereof.
8. The cell of claim 7 , wherein the poly(A) tail, the Kozak sequence, the 3′ untranslated region, the 5′ untranslated region, or the any combination thereof comprises one or more modified nucleosides.
9. The cell of claim 1 , wherein the synthetic, modified RNA is treated with an alkaline phosphatase.